Avation Medical is a technology company.
Avation Medical has raised $22.0M across 1 funding round.
Avation Medical has raised $22.0M in total across 1 funding round.
Avation Medical has raised $22.0M in total across 1 funding round.
Avation Medical's investors include Shangbay Capital, Sony Innovation Fund, Casey Tansey.
Avation Medical is a technology company specializing in neuromodulation and digital health, focused on developing non-invasive, wearable medical devices. Its flagship product, the Vivally® System, is the only FDA-cleared, physiologic closed-loop, at-home wearable neuromodulation device designed to treat symptoms of overactive bladder (OAB), including urge urinary incontinence (UUI) and urinary urgency. The device is worn on the ankle and delivers personalized electrical stimulation therapy in 30-minute sessions as infrequently as once per week, offering a drug-free, surgery-free alternative for patients. Avation serves adults suffering from OAB, aiming to improve their quality of life through accessible, patient-centered therapy supported by a companion mobile app[1][3][5].
Founded in 2016 and headquartered in Columbus, Ohio, Avation Medical was co-founded by Jill Schiaparelli (CEO) and Manish Vaishya (CTO), who brought extensive experience in medical technology and neuromodulation. The idea emerged from recognizing the limited appeal and accessibility of existing OAB treatments, which often involve drugs or invasive procedures. Early traction included FDA 510(k) clearance for Vivally and positive results from multi-center clinical trials demonstrating safety, efficacy, and high patient compliance. The company has since raised over $22 million to support commercial launch and scale its innovative wearable therapy[2][3][5].
Avation Medical rides the growing trend of wearable digital therapeutics and personalized medicine, leveraging advances in neuromodulation technology and real-time biosensing. The timing is favorable due to increasing demand for non-invasive, patient-friendly chronic condition management solutions and a healthcare shift toward home-based care. By providing a scalable, FDA-cleared wearable device that integrates digital health tools, Avation influences the broader ecosystem by expanding access to neuromodulation therapies and setting new standards for chronic bladder condition treatment[1][2][7].
Looking ahead, Avation Medical is positioned to expand the commercial reach of Vivally across the U.S. and potentially other geographies, supported by recent funding and regulatory clearances. The company is likely to leverage its platform technology to develop additional neuromodulation-based therapies for other clinical conditions, riding the wave of personalized, non-invasive digital therapeutics. As wearable health devices and closed-loop systems gain traction, Avation’s influence may grow significantly, reshaping treatment paradigms for chronic conditions and enhancing patient autonomy and quality of life[3][5].
Avation Medical has raised $22.0M across 1 funding round. Most recently, it raised $22.0M Series C in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $22.0M Series C | Shangbay Capital, Sony Innovation Fund, Casey Tansey |